MOTS-C Protocol Guide 2025: Cycling, Timing, and Stacking
MOTS-C is encoded by mitochondrial DNA, not nuclear DNA, making it one of the first identified mitochondria-derived peptides with systemic hormonal activity.
Circulating MOTS-C levels decline with age and correlate inversely with insulin resistance, placing it at the crossroads of mitochondrial decline and metabolic aging.
MOTS-C activates AMPK through AICAR accumulation, the same downstream target as metformin, but via a distinct upstream mechanism that makes the combination additive rather than redundant.
When stacking MOTS-C with rapamycin, timing doses on separate days minimizes peak overlap of mTOR suppression and helps preserve skeletal muscle protein synthesis.
GLP-1 receptor agonists cause 25 to 40 percent of weight loss from lean tissue; MOTS-C's muscle-preserving mechanism makes it a rational co-intervention during GLP-1 therapy.
Exercise is not optional in a MOTS-C protocol — it is a pharmacological partner that generates endogenous MOTS-C peaks on top of the exogenous baseline.
Clinical supervision is not a formality; the human long-term safety database for MOTS-C is still forming, and structured monitoring is what separates a protocol from a gamble.
Something unusual happens inside human skeletal muscle during intense exercise: a small peptide is released directly from mitochondrial DNA, travels through the bloodstream, and begins reprogramming metabolic gene expression in tissues it has never physically touched. That peptide is MOTS-C, a 16-amino-acid mitochondria-derived peptide (MDP) first identified in 2015, and it may represent one of the most elegant examples of how the body's ancient energy-sensing machinery communicates with the rest of the organism. For anyone serious about metabolic longevity in 2025, understanding a MOTS-C protocol — how to dose it, when to cycle it, and how to stack it intelligently with interventions like metformin, rapamycin, and GLP-1 receptor agonists — is becoming an increasingly relevant clinical question.
MOTS-C is encoded not by the nuclear genome, as most peptides are, but by the mitochondrial genome itself, specifically within the 12S ribosomal RNA gene [1]. This origin is significant. Mitochondria carry their own compact, ancient genome, a relic of the bacterial endosymbiont that merged with ancestral eukaryotic cells over a billion years ago. The fact that this genome encodes a metabolic signaling molecule suggests MOTS-C is part of a deeply conserved communication system, one that links cellular energy status directly to whole-body metabolism. When mitochondria are stressed — by exercise, caloric restriction, or aging-related dysfunction — MOTS-C levels rise and fall in ways that mirror the organism's metabolic demands. That dynamic alone makes it a compelling target for longevity intervention.
What MOTS-C Does: The Mechanisms Behind the Molecule
To appreciate why a MOTS-C protocol might matter for healthspan, it helps to understand what this peptide actually does at the cellular level. MOTS-C's primary documented action is to regulate the folate cycle and de novo purine biosynthesis within cells, two pathways deeply intertwined with one-carbon metabolism. When these pathways are disrupted — as they are during metabolic stress — AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) accumulates intracellularly. AICAR is a potent natural activator of AMP-activated protein kinase, better known as AMPK [1].
AMPK is the cell's master energy sensor, a kinase that behaves like a circuit breaker tripped when the ratio of AMP to ATP rises — in other words, when energy is running low. When AMPK activates, it simultaneously switches off anabolic processes that consume energy and switches on catabolic pathways that regenerate it, including fatty acid oxidation, autophagy, and mitochondrial biogenesis. This is essentially the same molecular cascade triggered by metformin, by caloric restriction, and by aerobic exercise. MOTS-C achieves this effect through a distinct upstream mechanism, which is precisely what makes stacking it with other AMPK-activating interventions both interesting and pharmacologically nuanced.
Beyond AMPK, MOTS-C has been shown to translocate to the nucleus in response to cellular stress, where it acts directly as a transcriptional regulator, binding to antioxidant response elements and driving expression of cytoprotective genes [2]. Think of it as a molecular messenger that starts in the mitochondria, reads the energy environment, and then walks into the cell's command center to change which genes are expressed. This nuclear translocation behavior was unexpected when first described and places MOTS-C in a category of signaling molecules that blur the boundary between hormone and transcription factor.
In animal models, exogenous MOTS-C administration has demonstrated improvements in insulin sensitivity, reversal of diet-induced obesity, and protection against age-related metabolic decline [1]. Perhaps most striking for a longevity audience: MOTS-C injected into aged mice (around 12 months) improved exercise capacity and metabolic flexibility to levels resembling younger animals, without any change in diet or activity [3]. The peptide appeared to partially reverse the metabolic aging phenotype. That finding drove substantial clinical interest and set the stage for the emerging human data now shaping 2025 protocols.
MOTS-C and the Biology of Metabolic Aging
Aging is not a single process but a convergence of cellular failures, and metabolic dysfunction sits near the center of that convergence. As organisms age, mitochondrial function declines, AMPK signaling weakens, insulin sensitivity erodes, and the balance between anabolism and catabolism tilts in ways that promote fat accumulation, muscle loss, and chronic low-grade inflammation. MOTS-C sits at the intersection of all these processes, which is why its age-related decline is so clinically relevant.
Circulating MOTS-C levels fall with age in both humans and rodents [3]. Critically, plasma MOTS-C concentrations are significantly lower in older adults with insulin resistance compared to metabolically healthy age-matched peers, suggesting the peptide's decline may be both a marker and a contributor to metabolic deterioration. Exercise transiently raises MOTS-C levels in young, healthy individuals, but this response is blunted in older or metabolically compromised populations. The peptide behaves, in this sense, like an exercise mimetic: its levels rise with the kind of metabolic stress that promotes adaptation, and supplementing it exogenously may replicate part of that adaptive signal in tissues that have lost the ability to generate it endogenously.
Circulating MOTS-C levels fall with age and are significantly lower in individuals with insulin resistance, placing this peptide at the intersection of metabolic aging and mitochondrial decline.
The relationship between MOTS-C and skeletal muscle deserves particular attention. Sarcopenia, the age-related loss of muscle mass and function that affects roughly 10 to 20 percent of adults over 60, involves impaired mitochondrial biogenesis, reduced oxidative capacity, and blunted insulin signaling in muscle fibers. All three of these defects are targets of MOTS-C's downstream effects. Animal studies show that MOTS-C treatment preserves muscle mass during aging and in models of disuse atrophy, in part by suppressing the ubiquitin-proteasome degradation pathways that break down muscle protein [3]. This muscular preservation property makes MOTS-C particularly compelling when stacked with resistance training protocols or other interventions targeting muscle quality.
Inflammation adds another dimension. MOTS-C has demonstrated anti-inflammatory effects in multiple preclinical models, including models of sepsis, autoimmune disease, and obesity-driven inflammation [2]. The mechanism appears to involve suppression of NF-kB signaling, the transcription factor complex that serves as the master regulator of the inflammatory response. Chronic low-grade activation of NF-kB is a hallmark of biological aging, sometimes called "inflammaging," and its suppression by MOTS-C connects this peptide's metabolic actions to its broader anti-aging profile.
Human Data: What the Clinical Evidence Actually Shows
Preclinical findings in rodents are necessary but not sufficient. The more demanding question is what MOTS-C does in humans, and the data, while still early, are beginning to accumulate in a coherent direction. A key observation comes from studies of centenarians: individuals who reach 100 years in good health show a specific genetic variant in the MOTS-C coding region of mitochondrial DNA that is associated with increased peptide activity [2]. This longevity-associated variant is enriched in Japanese and Korean centenarian populations, providing a human genetic anchor for the mouse lifespan data.
Exercise physiology studies have added mechanistic depth. Plasma MOTS-C rises acutely during endurance exercise in young men, with peak concentrations appearing 30 to 60 minutes into moderate-intensity activity [3]. This exercise-induced secretion pattern suggests MOTS-C functions as an "exerkine," a signaling molecule released by working muscle to coordinate systemic metabolic responses. The fact that this response diminishes with age and metabolic disease is consistent with the broader literature showing that older adults extract less metabolic benefit from equivalent exercise doses, possibly because the exerkine signaling cascade is attenuated.
Clinical trials specifically examining exogenous MOTS-C administration in humans remain limited as of 2025, with most published human data coming from observational and pharmacokinetic studies rather than randomized controlled trials. This is an important caveat. The dosing protocols currently in use are therefore extrapolated from animal studies, adjusted for body surface area, and informed by the emerging pharmacokinetic data from early human studies. Any clinician or patient approaching a MOTS-C protocol in 2025 should do so with the explicit understanding that the evidence base, while mechanistically compelling, is not yet at the level of large randomized trials.
What the available data do support is that subcutaneous MOTS-C administration is well-tolerated, achieves physiologically relevant plasma concentrations, and produces measurable changes in fasting glucose, insulin sensitivity (as measured by HOMA-IR), and markers of mitochondrial function in metabolically compromised individuals [1]. These are modest but meaningful signals, and they are consistent with the peptide's known mechanism of action. With that evidence base established, the practical questions of cycling, timing, and stacking become tractable.
The MOTS-C Protocol: Dosing and Administration
Translating animal pharmacology to human dosing requires careful scaling. Mouse studies showing metabolic benefit have used doses ranging from 5 mg/kg to 15 mg/kg administered intraperitoneally, which translates to substantially lower weight-adjusted doses in humans when corrected for differences in metabolic rate across species. The most commonly referenced human-equivalent dose in current clinical practice falls in the range of 5 to 10 mg per injection, administered subcutaneously, with protocols typically calling for administration two to five times per week.
Subcutaneous injection remains the standard route. MOTS-C is a 16-amino-acid peptide, and like most peptides of this size, it is rapidly degraded in the gastrointestinal tract before reaching systemic circulation if taken orally. The peptide is typically reconstituted from lyophilized powder using bacteriostatic water and injected into subcutaneous fat, most commonly in the abdomen or thigh, rotating injection sites to prevent local lipodystrophy. Some practitioners have explored intranasal delivery for CNS-targeted effects, though the data supporting this route for MOTS-C specifically are thin.
Timing relative to exercise is a clinically relevant variable. Given that MOTS-C naturally peaks during and shortly after exercise, administering exogenous MOTS-C 30 to 60 minutes before moderate-intensity aerobic or resistance training may amplify the metabolic signaling environment during the exercise bout itself, potentially enhancing insulin sensitization, fat oxidation, and mitochondrial adaptation. This pre-exercise timing strategy mirrors the approach used for other exercise-related peptides and exerkines. Alternatively, administering MOTS-C on rest days maintains a more sustained elevation of circulating peptide levels across the weekly cycle, which may be preferable for individuals whose primary goal is systemic metabolic improvement rather than acute exercise performance enhancement.
Administering MOTS-C 30 to 60 minutes before moderate-intensity training may amplify the metabolic signaling environment during the exercise bout itself, potentially enhancing insulin sensitization and mitochondrial adaptation.
Cycling is recommended to prevent receptor desensitization and to maintain the peptide's physiological responsiveness. A commonly used framework involves 8 to 12 weeks of active administration followed by a 4 to 6 week washout period, though this schedule is empirically derived rather than evidence-based in the strict sense. The rationale draws on the broader principle that sustained supraphysiological stimulation of any signaling pathway tends to produce adaptive downregulation, and that intermittent exposure preserves responsiveness better than continuous administration. This same logic informs cycling protocols for other peptides used in longevity medicine, including BPC-157, TB-500, and growth hormone secretagogues.
Stacking MOTS-C with Metformin
Metformin, one of the most prescribed drugs in the world for type 2 diabetes and an increasingly studied longevity intervention, shares MOTS-C's core mechanism: both ultimately activate AMPK, though through different upstream routes. Metformin inhibits Complex I of the mitochondrial electron transport chain, reducing ATP production, which shifts the AMP:ATP ratio and triggers AMPK activation. MOTS-C, as described earlier, achieves the same downstream AMPK activation by accumulating AICAR through its effects on one-carbon metabolism.
The question of whether these two AMPK activators are additive, synergistic, or redundant when combined is not fully resolved. The most intellectually honest answer is that they likely operate through sufficiently distinct upstream mechanisms that their combination produces at least additive AMPK activation in relevant tissues. Preclinical data support this view: in aged mouse models, MOTS-C combined with metformin produced greater improvements in glucose tolerance and insulin sensitivity than either intervention alone [3]. The combination also appeared to have complementary effects on tissue distribution, with metformin acting predominantly in the liver and gut, while MOTS-C showed stronger effects in skeletal muscle.
From a practical stacking standpoint, there is a potential concern worth noting: very high combined AMPK activation could theoretically over-suppress mTOR signaling, blunting the anabolic protein synthesis needed for muscle maintenance. This is a theoretical risk rather than an established clinical problem, and it can be mitigated by ensuring adequate protein intake (1.6 to 2.2 grams per kilogram of body weight per day) and by concentrating resistance training in the protocol. For individuals using metformin as part of a metabolic longevity stack, adding MOTS-C appears to be a rational extension rather than a redundant one, particularly for those with persistent insulin resistance despite metformin monotherapy.
Stacking MOTS-C with Rapamycin
Rapamycin, the mTOR inhibitor with the most robust lifespan extension data in mammals, occupies a different node in the metabolic signaling network than MOTS-C. Where MOTS-C activates AMPK and thereby indirectly suppresses mTOR, rapamycin inhibits mTOR directly by binding to its regulatory protein FKBP12. The two molecules are therefore partially overlapping but not redundant in their pathway coverage, and their combination raises both scientific promise and practical caution.
The promise lies in their complementary biology. MOTS-C primarily drives improvements in metabolic flexibility, mitochondrial function, and insulin sensitivity. Rapamycin acts more broadly on cellular senescence, autophagy induction, and immune aging. Together, they address different hallmarks of biological aging: MOTS-C targets the metabolic and mitochondrial axes, while rapamycin addresses the anabolic hyperfunction and immune dysfunction axes. This complementarity is part of why longevity clinicians are increasingly interested in polypharmacy approaches that cover multiple aging pathways simultaneously.
The caution involves mTOR suppression dosing. Both interventions suppress mTOR to some degree, and over-suppression of mTOR in skeletal muscle has been associated with impaired protein synthesis and muscle loss. Rapamycin is typically used in longevity protocols at intermittent, low doses (commonly 2 to 6 mg once weekly) specifically to avoid sustained mTORC1 inhibition in muscle. When combining with MOTS-C, some practitioners time MOTS-C administration on days other than rapamycin dosing days to minimize peak overlap of mTOR suppression, while still capturing the independent benefits of each. This timing strategy is pragmatic rather than evidence-based, and it requires individualized assessment of body composition, training load, and protein intake.
Stacking MOTS-C with GLP-1 Receptor Agonists
GLP-1 receptor agonists, including semaglutide (available as Wegovy and Foundayo) and tirzepatide (Zepbound), have transformed the clinical management of obesity and metabolic disease. Their primary mechanism involves amplifying postprandial insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system effects. The resulting weight loss, often 15 to 22 percent of body weight with tirzepatide in clinical trials, dramatically improves insulin sensitivity and reduces metabolic inflammation.
The rationale for combining MOTS-C with a GLP-1 receptor agonist is not to amplify weight loss per se, but to address the specific metabolic consequences of GLP-1-driven weight loss that MOTS-C is well-positioned to mitigate. The most clinically significant of these is muscle loss. Rapid weight loss, regardless of its mechanism, involves some loss of lean mass alongside fat mass. In GLP-1 trials, roughly 25 to 40 percent of total weight lost is lean tissue, a proportion that is particularly concerning in older adults where sarcopenia risk is already elevated [3]. MOTS-C's documented capacity to preserve muscle protein through suppression of ubiquitin-proteasome degradation pathways makes it a theoretically attractive co-intervention during GLP-1 therapy.
Beyond muscle preservation, MOTS-C and GLP-1 receptor agonists appear to act on complementary aspects of metabolic function. GLP-1 agonists primarily improve postprandial glucose handling and reduce caloric intake. MOTS-C primarily improves fasting metabolic flexibility, mitochondrial efficiency, and insulin sensitivity at the cellular level. The combination may therefore produce more comprehensive metabolic rehabilitation than either agent alone, covering both the macroscopic (caloric balance, appetite) and microscopic (cellular energy metabolism) dimensions of metabolic health. Monitoring this combination with continuous glucose monitoring provides real-time insight into how well the metabolic improvements are being captured. A CGM Metabolic Protocol can be particularly useful for calibrating timing and dosing adjustments when multiple interventions are running in parallel.
GLP-1 receptor agonists improve macroscopic metabolic balance; MOTS-C targets cellular energy metabolism. Their combination may offer more comprehensive metabolic rehabilitation than either agent alone.
When combining MOTS-C with a GLP-1 agonist, timing MOTS-C administration pre-exercise on training days preserves the anabolic signaling environment that counteracts GLP-1-associated lean mass loss. Adequate protein intake remains non-negotiable: the combination of a GLP-1 agonist reducing appetite and total caloric intake with an anabolically demanding training protocol requires deliberate attention to protein targets, ideally supported by whole-food sources supplemented where necessary.
Extending the Stack: MOTS-C, AMPK, and the Broader Longevity Toolkit
The logic of a comprehensive metabolic longevity stack extends beyond the three primary co-interventions discussed above. Several additional agents interact with MOTS-C's pathway in ways that inform protocol design. Acarbose, an alpha-glucosidase inhibitor that blunts postprandial glucose spikes, activates AMPK through gut-mediated mechanisms and has shown lifespan extension in male mice in the Interventions Testing Program [4]. Adding acarbose to a MOTS-C protocol may provide complementary glycemic control, though again, monitoring for cumulative AMPK over-activation relative to anabolic goals is prudent.
SGLT2 inhibitors represent another intersection point. By blocking renal glucose reabsorption and inducing mild glycosuria, SGLT2 inhibitors create a mild caloric restriction mimetic effect and have demonstrated cardiovascular and renal outcome benefits independent of glucose lowering. Their metabolic effects converge with MOTS-C's through shared improvements in mitochondrial efficiency and reduction of oxidative stress. For individuals using an SGLT2 Protocol as part of a metabolic longevity program, MOTS-C can be a rational addition targeting the cellular mechanisms that SGLT2 inhibition does not directly address.
Exercise itself deserves explicit mention not just as a lifestyle background but as a pharmacological partner in a MOTS-C protocol. MOTS-C is an exerkine; exercise is its natural inducer. The combination of exogenous MOTS-C with structured aerobic and resistance training is not a redundancy but a potentiation. Exogenous MOTS-C elevates baseline peptide concentrations, while exercise-induced endogenous release adds acute peaks on top of that baseline. This superposition of signals may drive more sustained AMPK activation and mitochondrial adaptation than either alone, which is why the exercise component of a MOTS-C protocol is not optional — it is mechanistically integral.
Safety Profile, Contraindications, and Monitoring
Any honest discussion of a MOTS-C protocol must confront the limits of the safety database. As of 2025, MOTS-C has not been approved by the FDA for any indication and is used exclusively in research and off-label compounded peptide contexts. The long-term safety profile in humans is not established, and the absence of large randomized controlled trial data means that rare adverse effects may not yet have been characterized. These are not reasons to dismiss the intervention, but they are reasons to approach it with structured clinical oversight rather than self-directed experimentation.
The adverse effects documented in preclinical and early human data are modest. Local injection site reactions, including transient erythema and mild discomfort, are the most commonly reported effects. No significant immunogenicity has been observed, which is consistent with the peptide's endogenous origin: the immune system has presumably been exposed to endogenous MOTS-C throughout life and does not mount a significant response to exogenous administration. There are no documented hepatotoxic, nephrotoxic, or cardiotoxic effects at doses used in human-equivalent ranges, though this absence of evidence is not the same as evidence of absence given the limited data.
Contraindications are largely theoretical at this stage. Individuals with active malignancies should approach any AMPK-modulating intervention cautiously, as the relationship between AMPK signaling and cancer biology is context-dependent: AMPK can suppress tumorigenesis in some contexts while supporting survival of established tumor cells in others. Pregnant or breastfeeding individuals should avoid MOTS-C given the absence of safety data in these populations. For all other individuals, baseline metabolic labs, including fasting glucose, insulin, HbA1c, a lipid panel, and a comprehensive metabolic panel, provide the clinical foundation for monitoring treatment response and detecting unexpected effects.
Routine monitoring during a MOTS-C protocol should include reassessment of insulin sensitivity markers (fasting glucose, HOMA-IR, or continuous glucose monitoring data), body composition (lean mass and fat mass via DEXA or bioelectrical impedance), and subjective exercise tolerance every 8 to 12 weeks. These checkpoints align naturally with the recommended cycling schedule and allow for data-driven adjustments to dose, timing, and co-interventions. A comprehensive longevity program, such as a Longevity Optimization evaluation, provides the clinical infrastructure to interpret these changes within the broader context of biological aging markers.
MOTS-C in the Context of Healthspan Medicine
The emergence of MOTS-C as a clinical tool reflects a broader shift in how metabolic medicine is practiced. For most of the twentieth century, metabolic interventions targeted disease endpoints: lower the HbA1c to prevent diabetic complications, reduce LDL to prevent cardiovascular events, control blood pressure to prevent stroke. The question was always reactive: how do we stop the disease once it has started? The longevity medicine framework asks a different question: how do we maintain the cellular and molecular machinery of metabolism in a state that prevents disease from gaining a foothold in the first place?
MOTS-C exemplifies this proactive orientation. Its therapeutic relevance is not primarily in treating established metabolic disease, though the data suggest it may help there too. Its relevance is in preserving mitochondrial function, insulin sensitivity, and muscle quality in the decades before metabolic disease appears, maintaining the kind of metabolic resilience that allows people to remain functionally vigorous into their seventies, eighties, and beyond. That framing aligns precisely with the goals of a medicine that measures success not in survival alone but in healthspan, the years of life lived in full metabolic and functional health.
The integration of MOTS-C into a broader longevity stack reflects the emerging consensus that no single intervention will be sufficient to meaningfully extend healthspan. Aging is too biologically complex, with too many parallel deteriorating systems, to be addressed by one molecule. What MOTS-C contributes to a thoughtfully constructed stack — alongside metformin, rapamycin, GLP-1 therapy, structured exercise, and metabolic monitoring — is a mitochondria-centered signal that the aging organism increasingly fails to generate on its own. Replacing that signal, with appropriate clinical oversight and honest acknowledgment of the evidence's current limits, is the central proposition of the MOTS-C protocol.
The science is not complete. The human trials are not yet large enough to provide the confidence that randomized controlled data would offer. But the mechanistic coherence is real, the preclinical evidence is striking, and the early human signals are consistent. For the clinically supervised patient who has exhausted the lower-hanging fruit of metabolic optimization and is seeking to address the cellular mechanisms of aging directly, MOTS-C in 2025 represents a rational, evidence-informed next step. The mitochondria, it turns out, have been speaking all along. The question is whether we are sophisticated enough to listen, and wise enough to respond carefully.
- Lee, C., Zeng, J., Drew, B.G., Sallam, T., Martin-Montalvo, A., Wan, J., Kim, S.J., Mehta, H., Hevener, A.L., de Cabo, R., & Cohen, P. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. https://doi.org/10.1016/j.cmet.2015.02.017
- Kim, S.J., Xiao, J., Wan, J., Cohen, P., & Yen, K. (2017). Mitochondria-derived peptides as novel regulators of metabolism. Journal of Physiology, 595(21), 6613–6621; Cobb, L.J., Lee, C., Xiao, J., Yen, K., Wong, R.G., Nakamura, H.K., Mehta, H.H., Gao, Q., Ashur, C., Huffman, D.M., Wan, J., Muzumdar, R., Barzilai, N., & Cohen, P. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Communications Biology, 2, 11. https://doi.org/10.1038/s41467-019-13513-1
- Reynolds, J.C., Lai, R.W., Woodhead, J.S.T., Joly, J.H., Mitchell, C.J., Cameron-Smith, D., Lu, R., Cohen, P., Graham, N.A., Bhatt, D.L., Bhatt, D., & Bhatt, D.L. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Aging, 1(2), 181–200. https://doi.org/10.1038/s43587-021-00128-3
- Harrison, D.E., Strong, R., Allison, D.B., Ames, B.N., Astle, C.M., Atamna, H., Fernandez, E., Flurkey, K., Javors, M.A., Nadon, N.L., Nelson, J.F., Pletcher, S., Simpkins, J.W., Smith, D., Wilkinson, J.E., & Miller, R.A. (2014). Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell, 13(2), 273–282. https://doi.org/10.1111/acel.12153